Vi Polysaccharide

Developed for: typhoid fever
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID)

today NCT00326443 · Ph 1

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT00326443	Feb 2006 → Sep 2007	typhoid fever	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT01437267 Comparator	Oct 2011 → Aug 2012	typhoid fever	Novartis	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Vi Polysaccharide	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00326443 ↗ 1 NCT01437267 ↗
Modality	Vaccine	“licensed purified Vi polysaccharide vaccine” NCT00326443 ↗
Route	Intramuscular	“Three weeks later, all volunteers will receive 25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine by the intramuscular route.” NCT00326443 ↗